Human(7428) Summary: Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed. [provided by RefSeq, Jul 2008]
Save up to 60% per TRCN when you buy a set with the same options.
MISSION® siRNAs have been designed using a world-class siRNA design algorithm licensed from Rosetta Inpharmatics, a leader in advanced siRNA research. The Rosetta-powered siRNA design algorithm has been optimized with over 3 years of continuous development for enhanced performance in RNAi applications. New and critical siRNA design rules incorporated into the latest algorithm lead to increased target specificity and knockdown for low abundance messages.
Validated MISSION® siRNAs have been functionally validated in Hela cells by Sigma scientists to Knockdown gene expression by 75% or greater. With Validated MISSION® siRNAs, we have done the upfront validation work, so that you do not have to.